Breast and Ovarian Cancer Risk and Prevention
Research Studies
Neoadjuvant Trial of Lapatinib for the Treatment of Women with DCIS Breast Cancer
Lapatinib was recently approved by the FDA for use in advanced breast cancer. It remains an investigational drug for the treatment of women with DCIS (ductal carcinoma in situ). We do not yet know if it is useful or safe as a chemopreventive agent for DCIS. The main purpose of this study is to begin to collect information and try to learn more about the most effective dose of lapatinib, whether the drug will prevent the spread of cancer, and the other changes to breast cancer tissue and breast cancer cells.
Who is Eligible?
Women, age 21 or older, with DCIS positive for either EGFR or erbB2 (or both) will be considered for enrollment.
How Long is the Study?
This is a 2-6 week study where patients are given either lapatinib in one of the three doses or placebo before their breast cancer surgery.
How can I get more information about the Lapatinib Study?
For more information please contact:
Carleen Gentry, MA
Carleen_gentry@dfci.harvard.edu
(617) 632-5399
